Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05226663 · ClinicalTrials.gov registry record · Phase 2

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

A Phase 2 study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
36
Enrollment target
3
Study locations

NCT05226663 is a Phase 2 study of Breast Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05226663, a Phase 2 study of Breast Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial tests whether \[18F\]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery. \[18F\]FluorThanatrace is a new radioactive tracer, which is a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, \[18F\]FluorThanatrace. Because some cancers take up \[18F\]FluorThanatrace it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. \[18F\]FluorThanatrace by PET/CT may help detect the activity of a certain enzyme in the body that may be related to cancer growth in patients with breast cancer.

Conditions Studied

Breast Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • RADIATION Fluorine F 18 Fluorthanatrace

Study Locations (3)

Missouri

  • Siteman Cancer Center at Washington University - St Louis

Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center - Philadelphia

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2023-02-27
Est. Completion 2026-08-20
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05226663

The ClinicalTrials.gov registry entry for NCT05226663 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (95% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.

NCT05226663 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Missouri, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT05226663 about?

NCT05226663 is a clinical study titled "A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer". This phase II trial tests whether \[18F\]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery. \[18F\]FluorThanatrace is a new radioactive tracer, which is a type o...

What is the current status of trial NCT05226663?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-02-27. Estimated completion is 2026-08-20.

What conditions does trial NCT05226663 study?

This clinical trial studies the following conditions: Breast Carcinoma.

What interventions are being tested in trial NCT05226663?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fluorine F 18 Fluorthanatrace (RADIATION).

Who is sponsoring clinical trial NCT05226663?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05226663 being conducted?

This trial has 3 study locations across Missouri, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Carcinoma

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.